Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Georgia for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Georgia only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Georgia (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Jonathan Bender (NPI 1649228651)

Field	Value
Entity Type	Individual
Organization	Jonathan Bender
Address	1265 Highway 54 W Ste 4200
City	Fayetteville
State	GA
ZIP	30214
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	May 4, 2006

Payer Source	Total Paid
Medicare	$2.6M
Medicaid	$0

Key Findings

This NPI is a Hematology & Oncology physician whose Medicare billing is dominated by outpatient biologic and infusion services; the code mix is led by high-revenue oncology immunotherapy and supportive biologics such as J9271 (pembrolizumab), J0897 (denosumab), and J1569 (immune globulin), along with chemotherapy administration codes (96413, 96417, 96402) that together indicate an infusion-focused oncology practice rather than a predominantly inpatient or surgical operation. The presence of ferric derisomaltose (J1437) and multiple growth-factor/ESA codes (J2506, J1442, J0881) further supports a service line centered on both cancer-directed therapy and frequent supportive care infusions.

Revenue concentration in Medicare is highly skewed: the precomputed top 3 Medicare codes (J9271, J0897, J1569) account for 75.9% of this provider's total Medicare revenue, with J9271 alone representing 56.3% of Medicare revenue. That degree of concentration around a single high-cost immunotherapy suggests the practice’s financial performance is closely tied to pembrolizumab administration volumes and pricing patterns.

Payer mix is effectively single-payer in the available data: total Medicare revenue is $2.6M and there is no Medicaid billing on file, meaning this provider’s public-payer footprint in the dataset is driven entirely by Medicare. The absence of Medicaid billing may reflect the practice’s patient mix, contracting, or billing focus rather than lower clinical activity, but it does mean analytic comparisons should treat the provider as effectively Medicare-only in this source.

On national competitive standing for key drugs, this provider ranks at the high end: J9271 ranks #72 of 1841 providers nationally (96th percentile; notably above typical national volume), and J0897 ranks #339 of 10057 providers nationally (97th percentile; notably above typical national volume). By contrast J1569 is more modest at rank #169 of 542 (69th percentile; typical, unremarkable volume), so the provider is a major national-volume participant for select oncology biologics while remaining typical for certain supportive immunoglobulin services.

Several non-drug service and administration codes also show above-typical activity, consistent with an active infusion clinic: 96413 ranks #260 of 7514 (97th percentile; notably above typical national volume) and 96402 ranks #153 of 4765 (97th percentile; notably above typical national volume). High percentile ranking on both chemotherapy administration and common office E/M code 99213 (rank #12155 of 457151, 97th percentile; notably above typical national volume) indicates both procedural infusion throughput and a robust volume of established outpatient follow-up visits.

Claim-count and unit patterns point to frequent, low-dollar supportive therapies alongside high-revenue biologics: examples include J0881 with 15.2K claims at $2 avg paid/claim and J1442 with 18.1K claims at $1 avg paid/claim, contrasted with J9271’s 34.2K claims at $43 avg paid/claim producing the single largest revenue line. This mix signals an operational model that administers many low-cost supportive injections (growth factors, ESAs) in parallel with fewer but revenue-dominant immunotherapy doses.

The provider has a long tenure in the NPI file (NPI enumerated 2006-05-04, ~20 years ago), which combined with the high national percentiles on key infusion and oncology codes suggests an established regional infusion operation with sustained Medicare-facing activity; analysts considering market entry, network contracting, or utilization benchmarking should treat this clinician as an experienced, infusion-centric hematology/oncology practice with concentrated revenue exposure to a small number of biologic agents.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

50 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	34,200	$40	$1.5M
J0897	Injection, denosumab, 1 mg	18,420	$20	$331.6K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	5,150	$40	$180.3K
J1437	Injection, ferric derisomaltose, 10 mg	9,700	$20	$155.2K
Q5123	Injection, rituximab-arrx, biosimilar, (riabni), 10 mg	3,020	$40	$105.7K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	700	$100	$71.5K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	760	$70	$49.1K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	450	$100	$44.1K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	15,200	$1	$30.4K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	420	$70	$29.8K

Showing 1–10 of 50

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 50 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Georgia Distribution

Jonathan Bender — 10 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Georgia

Full comparison — all codes billed, vs. state median

50 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	2	40	15,200	$40	$767.3K
J1569	2	10	4,710	$40	$237.6K
Q5123	3	10	3,410	$30	$120.5K
J0897	13	290	2,460	$20	$90.2K
J1437	2	30	2,850	$20	$56.4K
J0881	9	20	15,200	$1	$37.1K
J2506	7	10	460	$80	$34.1K
J1454	12	20	80	$330	$25.9K
96413	5	160	170	$90	$20.3K
J1442	4	10	20,460	$1	$20K

Showing 1–10 of 50

Related Providers

Other providers that share a Tax Identification Number (TIN) with Jonathan Bender, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Vasileios Assikis	GA	Hematology & Oncology Physician	$3M	$0
Minesh Patel	GA	Hematology & Oncology Physician	$2.4M	$0
Vipin Ramprasad Lohiya	GA	Hematology & Oncology Physician	$2.3M	$0
William Jonas	GA	Hematology & Oncology Physician	$1.8M	$0
Trevor Feinstein	GA	Hematology & Oncology Physician	$1.4M	$0
Jay Rhee	GA	Hematology & Oncology Physician	$871.7K	$0
Nikita Amin	GA	Hematology & Oncology Physician	$444.2K	$0

Nearby Providers

Other providers in the same ZIP code as Jonathan Bender, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Summit Endoscopy Center	GA	Ambulatory Surgical Clinic/Center	$1.4M	$0
Board Of Commissioners Of Fayette County	GA	Land Ambulance	$693.7K	$224.7K
James Sandwich	GA	Dermatology Physician	$584.8K	$0
Georgia Urology Fayette Asc	GA	Ambulatory Surgical Clinic/Center	$504.4K	$0
Paul Feldman	GA	Plastic Surgery Physician	$483.9K	$0
Assured Care Ems LLC	GA	Land Ambulance	$457.1K	$0
Eye Consultants: Fayetteville Surgery Center	GA	Ophthalmology Physician	$449.7K	$0
Barbara Conlon	GA	Nurse Practitioner	$446.2K	$0
Pca Interventional Spine At Fayette, LLC	GA	Pain Clinic/Center	$434.5K	$0
Mobin Shah	GA	Hospitalist Physician	$380.8K	$0

Jonathan Bender — Billing Profile & Reimbursement Data

Sign up for Jonathan Bender — Billing Profile & Reimbursement Data policy alerts

Jonathan Bender — Billing Profile & Reimbursement Data

Sign up for Jonathan Bender — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References